TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05382728
Drug: TY-9591
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of TY-9591 is 160 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study: NCT05717582
Drug: androgen deprivation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive systemic ADT.
Study: NCT05009966
Drug: SYSA1801 for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYSA1801 will be administered intravenously (IV) on Day 1 of every 21-day cycle. Individual subjects may continue study treatment until there is evidence of disease progression (clinical or radiologic) judged by Investigators, unacceptable toxicity or other reasons for treatment discontinuation.
Study: NCT05240131
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered orally twice a day.
Study: NCT04652284
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg
Study: NCT05604937
Drug: Merislon
Normalized name: Merilog
Approvals — FDA: no, EMA: no, PMDA: no
Description: Merislon (Betahistine Mesilate Tablets), specification 6mg, Sinopharm H20040130, Eisai (China) Pharmaceutical Co., LTD., is given to patients of the control group, for 2 weeks, 6mg a day, three times a day.
Study: NCT05110807
Drug: TQB3617
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3617 is a BET inhibitor.
Study: NCT05382728
Drug: placebo TY-9591
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of placebo TY-9591 is 160 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study: NCT04873531
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the NS group, neostigmine normal saline (0.09 cc/kg; the same volume of the group N) will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery.
Study: NCT05909423
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral influenza vaccine treatment, administered via endoscopic procedure
Study: NCT04750135
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04274023
Drug: TSR-042
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSR-042 is an IgG4 humanized monoclonal antibody that binds with high affinity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2.
Study: NCT05376670
Drug: Intravesical aminoglycoside instillations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overnight instillation of an aminoglycoside (CIC), varying treatment regimens
Study: NCT05281185
Drug: standard half-life FVIII concentrates with weight-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard half-life FVIII concentrates with weight-based dosing, that current patients' regimen before enrolling in this study
Study: NCT05037591
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo lactose powder (1.68 g/70kg BW day-1).
Study: NCT05462730
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
Study: NCT04885972
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle solution
Study: NCT05681312
Drug: systemic proteolytic enzyme (Tibrolin)
Normalized name: PROTEOLYTIC ENZYME
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibrolin is a fixed dose combination of(Trypsin 48 mg, Bromelain 90 mg) and a bioflavonoid (Rutoside 100 mg)
Study: NCT05702879
Drug: TNF Inhibitor
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Start of standard therapy
Study: NCT05702879
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Start of standard therapy
Study: NCT04920903
Drug: COR588
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing doses of COR588 will be administered for cohorts 1-4 in the single ascending dose phase and for cohorts 1-4 in the multiple ascending dose phase.
Study: NCT04920903
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered for cohorts 1-4 in the single ascending dose phase and for cohorts 1-4 in the multiple ascending dose phase.
Study: NCT06195163
Drug: No pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pretreatment prior to the ovarian stimulation in the control group.
Study: NCT05998551
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intrathecal injection of fentanyl added to hyperbaric bupivacaine
Study: NCT00000824
Drug: Lymphocytes, Activated
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04882319
Drug: HP-5000 Topical Patch
Normalized name: Capzasin-HP Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP-5000, placebo and saline will be administered simultaneously
Study: NCT04882319
Drug: HP-5000 Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP-5000, placebo and saline will be administered simultaneously
Study: NCT05161806
Drug: SOK583A1 (40 mg/mL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOK583A1 provided in a Prefilled Syringe (PFS), which includes 2 mg aflibercept in 0.05 mL for IVT administration
Study: NCT05352165
Drug: Other individualized treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other individualized treatments based on organoids drug sensitivity
Study: NCT06277492
Drug: Single ascending doses SUL-238
Approvals — FDA: no, EMA: no, PMDA: no
Description: PART 1: SUL-238 single ascending doses
Study: NCT06277492
Drug: Single dose Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PART 1: Placebo single dose
Study: NCT05813795
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Injection with matched volume
Study: NCT06277492
Drug: Single dose SUL-238
Approvals — FDA: no, EMA: no, PMDA: no
Description: PART 2: SUL-238 single dose for pharmacokinetics
Study: NCT06277492
Drug: Multiple doses Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PART 3: Placebo multiple doses
Study: NCT04973124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: These participants will not receive intraoperative dexmedetomidine.
Study: NCT06277492
Drug: 2000 mg SUL-238 single dose for pharmacokinetics (food effect)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PART 2B: 2000 mg single dose of SUL-238
Study: NCT06277492
Drug: Single dose placebo (food effect)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PART 2B: Placebo single dose
Study: NCT04646889
Drug: AR882 Single Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of AR882
Study: NCT04646889
Drug: AR882 Multiple Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR882 taken once daily for 14 days
Study: NCT06322394
Drug: high-dose BXOS110
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg/kg, maximum dose not exceeding 300 mg，Participants received one administration by intravenous infusion.
Study: NCT01659515
Drug: Arbekacin Sulfate
Normalized name: arbekacin sulfate
DrugBank: Arbekacin (DB06696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous arbekacin in a total daily dose of 5-7 mg/kg
Study: NCT06322394
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Does not contain any test drug active ingredients，Participants received one administration by intravenous infusion.
Study: NCT06051565
Drug: Polysaccharide superparamagnetic iron oxide injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysaccharide superparamagnetic iron oxide injection can be used for the treatment of iron-deficiency anemia and for magnetic resonance imaging enhancement.
Study: NCT06204419
Drug: XH-S002 （A）
Approvals — FDA: no, EMA: no, PMDA: no
Description: XH-S002 powder will be administered orally as per assigned treatment regimen.
Study: NCT05965531
Drug: Trifluridine/Tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-102 is given in a dose of 35 mg/m2, twice daily on the 1st to 5th and 8th to 12th days of the period of neoadjuvant radiotherapy.
Study: NCT06383871
Drug: HRS-7058 capsule/ HRS-7058 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-7058 capsule/ HRS-7058 tablet
Study: NCT04302324
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given as 500mg oral capsule
Study: NCT05989724
Drug: SON-DP
Normalized name: prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution for IV administration
Study: NCT05102292
Drug: HLX208
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX208 450mg bid po
Study: NCT05727072
Drug: LY3848575
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT05727072
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT05727072
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT04666298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously injected on Day 1, 90, and 270.
Study: NCT05771675
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40Mg Oral Tablet
Study: NCT05771675
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Simvastatin Placebo tablet
Study: NCT04665375
Drug: DOR/3TC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: switch antiretroviral regimen to doravirine/lamivudine/tenofovir disoproxil fumarate once daily for 1 year
Study: NCT05387707
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo tablets administered twice daily
Study: NCT05387707
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Cream applied by study subjects to skin lesions once a day until control is achieved, then as needed
Study: NCT05029401
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to the IMP (DMX-1002)
Study: NCT05375305
Drug: SHR8554 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR8554 Injection; high dose
Study: NCT05375305
Drug: SHR8554 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR8554 Injection; low dose
Study: NCT04975074
Drug: Iron
Normalized name: Iron
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One of each type of iron was taken orally according to the instructions and followed every two weeks
Study: NCT05907330
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will administer the study drug once a day after a meal
Study: NCT05337774
Drug: [18F]PI-2620
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participant will be injected with 5 mCi (185 MBq) \[18F\]PI-2620 via a short line which will be placed in an intravenous line in an antecubital vein. Subjects will be placed in the scanner after injection and dynamic scans will be acquired for 0 to 60 minutes post injection.
Study: NCT06476366
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azathioprine will be started at 0.3mg/kg. Anticipated response is after atleast 1 month so testing will be done thereafter ( after checking initial safety profile)
Study: NCT06476366
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be started at 10mg/week and
Study: NCT05510115
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules will be matched in size and color to empagliflozin capsules. Each placebo capsule will contain the following inactive ingredients: microcrystalline cellulose magnesium, stearate, dicalcium phosphate, and silicone dioxide.
Study: NCT06326502
Drug: ETN101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT05195749
Drug: 101-PGC-005 ('005) + SOC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three consecutive days of '005 administration
Study: NCT05195749
Drug: Placebo + SOC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three consecutive days of placebo administration
Study: NCT05480592
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as a tablet
Study: NCT05060432
Drug: SOC chemotherapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC chemotherapies in 1L mNSCLC
Study: NCT00000674
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00000674
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04436978
Drug: Guideline-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-directed therapy (edoxaban + P2Y12 inhibitor, aspirin limited to in-hospital use or up to 30 days in selected high-risk patients)
Study: NCT04781387
Drug: CRS3123
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug dosed at 200 mg PO BID (treatment arm A) or 400 mg PO BID (treatment arm B) for total of 10 days
Study: NCT05372874
Drug: Direct Acting Antivirals
Normalized name: DIRECT ACTING ANTIVIRALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: hepatitis C patients will be treated by direct acting antiviral drugs (DAAs)for 12 weeks.
Study: NCT05346783
Drug: TJO-083
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diquafosol ophthalmic sodium solution, 1 drop 3 times a day
Study: NCT06495164
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor
Study: NCT05154630
Drug: TQB2858 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2858 is a Programmed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β(TGF-β) double antibody.
Study: NCT06120556
Drug: GLP-1 receptor agonist
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients initiating a GLP-1 receptor agonist (i.e. liraglutide, dulaglutide, semaglutide) will be included in the study.
Study: NCT03744663
Drug: Suboxone® SL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be started and titrated to optimal Suboxone® SL dose for 14 days. After the 14 day induction phase, the subject will be started on the treatment to which they were randomized to two groups one of which will be Suboxone® SL.
Study: NCT06120816
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric Oxide Releasing Mouthwash will be self-administered by the participant three times throughout the day for 21 days. The intervention solution will be poured into their mouth from a medication cup containing 20 mL of the solution. Total exposure to study intervention will be a maximum of 63 treatments totaling 1,260 mL. All participants will be monitored for 7 days post-last treatment dose (to Day 28).
Study: NCT03744663
Drug: Sublocade®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be started and titrated to optimal Suboxone® SL dose for 14 days. After the 14 day induction phase, the subject will be started on the treatment to which they were randomized, either Suboxone® SL or Sublocade®. Subjects with significant opioid craving (\> 20 mm on the Opioid Craving Visual Analog Scale) or withdrawal (a score of \> 12 on the Clinical Opiate Withdrawal Scale) after 14 days of treatment will be started on Sublocade® only at the consensus of the research team. Otherwise they will undergo an additional 7 day titration period. Study drug with Sublocade® group: Patients assigned to this group will receive the study drug (300 mg subcutaneously) every 4 weeks for a total of 6 doses along with weekly therapy. The location and specifications of its application will follow the recommendations by the FDA previously published.
Study: NCT06031454
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral
Study: NCT06031454
Drug: Leritrelvir
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT04880512
Drug: SYHX 1901 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYHX 1901, oral tablets, in fasted state
Study: NCT04880512
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, oral tablets, in fasted state
Study: NCT05505214
Drug: Bacterial decolonization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Validated decolonization regimen consisting of intranasal 2% mupirocin ointment applied twice daily as well as chlorhexidine wash used daily to the body. This regimen is conducted by the patient for 5 consecutive days prior to the start of RT and is repeated for an additional five days every other week continuing until either the development of moist desquamation or 2 weeks after the completion of RT.
Study: NCT05615012
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT05615012
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT05615012
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT05354752
Drug: VC005 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: VC005 groups repeat administration for 7 days
Study: NCT05354752
Drug: VC005 Placebo tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: VC005 placebo groups repeat administration for 7 days
Study: NCT05201560
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients of this group will receive Fentanyl
Study: NCT05887895
Drug: INS062 injection、INS068 injection、HR20014 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: INS062 injection：A single dose of 0.4 DU/kg is administered to healthy subjects.~INS068 injection：A single dose of 0.4 U/kg is administered to healthy subjects.~HR20014 injection：A single dose of 0.4 U/kg is administered to healthy subjects.
Study: NCT05847439
Drug: [14C]BMS-986419
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05561530
Drug: ALG-125755
Normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
Approvals — FDA: no, EMA: no, PMDA: no
Description: single or multiple doses of ALG-125755
Study: NCT05561530
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single or multiple doses of placebo
Study: NCT04995159
Drug: Single anti-platelet therapy
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first year after PCI. Aspirin will be discontinued one year after surgery and clopidogrel will be continued until 5 years after surgery.
Study: NCT04995159
Drug: Dual anti-platelet therapy
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first year after PCI. Patients continue to take dual antiplatelet (DAPT) drugs, including aspirin and clopidogrel, for 2 more years; then aspirin will be used alone from the 4th year to the 5th year.
Study: NCT03747328
Drug: ABI-009
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: nanoparticle albumin bound sirolimus
Study: NCT04670666
Drug: MADALENA ASSOCIATION
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Madalena association coated tablet.
Study: NCT05738759
Drug: Epidural Anesthetic Cocktail
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: The anesthetic cocktail, consists of triamcinolone 40 mg, marcaine 5 mg, and morphine 3 mg, is soaked in the gelfoam size 1x2 cm and applied on the epidura before removal of the endoscope.
Study: NCT05738759
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is soaked with NSS in the gelfoam size 1x2 cm as well and applied on the epidura before removal of the endoscope.
Study: NCT04780841
Drug: RDX013
Approvals — FDA: no, EMA: no, PMDA: no
Description: RDX013 is an experimental drug that is a potassium secretagogue
Study: NCT04780841
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment that looks identical to experimental treatment
Study: NCT00545207
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po monthly for 2 years
Study: NCT04784910
Drug: DWP14012 20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 20mg, tablet, orally, once daily for up to 24 weeks
Study: NCT04784910
Drug: DWP14012 20mg placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 20mg placebo-matching tablet, orally, once daily for up to 24 weeks
Study: NCT04072471
Drug: Zurampic®
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-interventional study where patients are exposed to Zurampic® plus a xanthine oxidase inhibitor (allopurinol or febuxostat) during the normal course of clinical practice
Study: NCT04072471
Drug: Control group: xanthine oxidase inhibitor monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-interventional study where patients are exposed to xanthine oxidase inhibitor monotherapy (allopurinol or febuxostat) during the normal course of clinical practice
Study: NCT05971654
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azithromycin.:500 mg PO once for 5 days every month
Study: NCT06366568
Drug: fluoride toothpaste containing 1450 ppm of MFP in a PCC base
Approvals — FDA: no, EMA: no, PMDA: no
Description: toothbrushing 2x a day for 2 minutes each time
Study: NCT05978908
Drug: FC-12738
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retro enversio pentapeptide of thymopentin
Study: NCT04823962
Drug: Placebo hydrogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo hydrogel